title: Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.
abstract: Currently, quantitative prediction of the impact of genetic polymorphism and drug-drug interactions mediated by cytochromes, based on in vivo data, is made by two separate methods and restricted to a single cytochrome. We propose a unified approach for describing the combined impact of drug-drug interactions and genetic polymorphism on drug exposure. It relies on in vivo data and uses the following three characteristic parameters: one for the victim drug, one for the interacting drug, and another for the genotype. These parameters are known for a wide range of drugs and genotypes. The metrics of interest are the ratio of victim drug area under the curve (AUC) in patients with genetic variants taking both drugs, to the AUC in patients with either variant or wild-type genotype taking the victim drug alone. The approach was evaluated by external validation, comparing predicted and observed AUC ratios found in the literature. Data were found for 22 substrates, 30 interacting drugs, and 38 substrate-interacting drug couples. The mean prediction error of AUC ratios was 0.02, and the mean prediction absolute error was 0.38 and 1.34, respectively. The model may be used to predict the variations in exposure resulting from a number of drug-drug-genotype combinations. The proposed approach will help (1) to identify comedications and population at risk, (2) to adapt dosing regimens, and (3) to prioritize the clinical pharmacokinetic studies to be done.
authors.affiliation: Hospices Civils de Lyon, Université de Lyon, Université Lyon 1, 69000, Lyon, France, michel.tod@chu-lyon.fr.
authors.forename: Michel
authors.initials: M
authors.lastname: Tod
authors.forename: Christina
authors.initials: C
authors.lastname: Nkoud-Mongo
authors.forename: François
authors.initials: F
authors.lastname: Gueyffier
mesh_terms: D051544:Cytochrome P-450 CYP3A / Q000235:genetics / Q000502:physiology*; D004347:Drug Interactions / Q000235:genetics*; D005544:Forecasting; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics*
chemical_list: D051544:Cytochrome P-450 CYP3A
references.citation: J Clin Psychopharmacol. 2006 Apr;26(2):135-42
references.pmid: 16633141
references.citation: Anesth Analg. 2006 May;102(5):1569-72
references.pmid: 16632844
references.citation: Br J Clin Pharmacol. 2005 Jul;60(1):61-8
references.pmid: 15963095
references.citation: Eur J Clin Pharmacol. 2007 Oct;63(10):941-9
references.pmid: 17676319
references.citation: Clin Pharmacol Ther. 1992 Nov;52(5):479-86
references.pmid: 1424422
references.citation: J Clin Pharmacol. 2010 Feb;50(2):214-25
references.pmid: 19948945
references.citation: Drug Metab Pharmacokinet. 2005 Feb;20(1):55-64
references.pmid: 15770075
references.citation: Br J Clin Pharmacol. 2004 Apr;57(4):487-94
references.pmid: 15025747
references.citation: Clin Pharmacokinet. 2013 Mar;52(3):199-209
references.pmid: 23344982
references.citation: Drug Metab Dispos. 2001 Oct;29(10):1284-9
references.pmid: 11560871
references.citation: Clin Pharmacokinet. 2011 Aug;50(8):519-30
references.pmid: 21740075
references.citation: Br J Clin Pharmacol. 2002 Apr;53(4):393-7
references.pmid: 11966672
references.citation: Pharmacopsychiatry. 2008 Nov;41(6):258-9
references.pmid: 19067264
references.citation: Fundam Clin Pharmacol. 2004 Feb;18(1):113-23
references.pmid: 14748763
references.citation: Drug Metab Dispos. 2007 Feb;35(2):246-55
references.pmid: 17093004
references.citation: Eur J Pharm Sci. 2003 Oct;20(2):223-32
references.pmid: 14550889
references.citation: Clin Pharmacol Ther. 1999 Sep;66(3):265-74
references.pmid: 10511062
references.citation: J Clin Psychopharmacol. 2002 Apr;22(2):174-82
references.pmid: 11910263
references.citation: Clin Pharmacol Ther. 2008 Nov;84(5):589-94
references.pmid: 18650803
references.citation: Am J Cardiol. 2004 Nov 15;94(10):1319-21
references.pmid: 15541258
references.citation: AAPS J. 2009 Jun;11(2):300-6
references.pmid: 19418230
references.citation: Drug Metab Dispos. 2008 Jul;36(7):1242-8
references.pmid: 18378563
references.citation: Clin Pharmacol Ther. 2003 Oct;74(4):334-40
references.pmid: 14534520
references.citation: Drug Metab Dispos. 2011 Dec;39(12):2329-37
references.pmid: 21930825
references.citation: Nat Rev Drug Discov. 2007 Feb;6(2):140-8
references.pmid: 17268485
references.citation: Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:37-44
references.pmid: 14616412
references.citation: Clin Pharmacokinet. 2008;47(12):779-92
references.pmid: 19026034
references.citation: Clin Pharmacol Ther. 2004 Mar;75(3):191-7
references.pmid: 15001970
references.citation: Eur J Clin Pharmacol. 2012 Jan;68(1):29-37
references.pmid: 21739267
references.citation: Antimicrob Agents Chemother. 2007 Oct;51(10):3617-26
references.pmid: 17646413
references.citation: Clin Pharmacol Ther. 2000 May;67(5):466-77
references.pmid: 10824625
references.citation: Clin Pharmacokinet. 2007;46(8):681-96
references.pmid: 17655375
references.citation: Br J Pharmacol. 2010 Jun;160(4):919-30
references.pmid: 20590588
references.citation: Drug Metab Dispos. 2000 Sep;28(9):1031-7
references.pmid: 10950845
references.citation: Clin Pharmacol Ther. 1999 Dec;66(6):642-6
references.pmid: 10613621
references.citation: Fundam Clin Pharmacol. 1996;10(3):314-8
references.pmid: 8836707
references.citation: J Clin Psychopharmacol. 1996 Jun;16(3):247-52
references.pmid: 8784658
references.citation: J Clin Pharmacol. 2009 May;49(5):574-81
references.pmid: 19398604
references.citation: Clin Pharmacol Ther. 2007 May;81(5):679-84
references.pmid: 17301736
references.citation: Br J Clin Pharmacol. 2008 Nov;66(5):660-6
references.pmid: 18754843
references.citation: Clin Pharmacol Ther. 1989 Apr;45(4):348-55
references.pmid: 2495208
references.citation: AAPS J. 2013 Apr;15(2):415-26
references.pmid: 23319287
references.citation: Br J Clin Pharmacol. 1992 Mar;33(3):275-80
references.pmid: 1576047
references.citation: Eur J Clin Pharmacol. 2002 Sep;58(6):423-9
references.pmid: 12242602
references.citation: Br J Clin Pharmacol. 2011 Jan;71(1):72-87
references.pmid: 21143503
references.citation: Clin Pharmacol Ther. 2002 Sep;72(3):238-46
references.pmid: 12235444
references.citation: Clin Pharmacol Ther. 2001 Apr;69(4):266-73
references.pmid: 11309556
references.citation: Clin Pharmacokinet. 2008;47(10):669-80
references.pmid: 18783297
references.citation: Antimicrob Agents Chemother. 2002 Aug;46(8):2546-53
references.pmid: 12121931
references.citation: Clin Pharmacol Ther. 1994 Mar;55(3):256-69
references.pmid: 8143391
references.citation: Drug Metab Dispos. 2011 Jun;39(6):1070-8
references.pmid: 21406602
references.citation: Clin Pharmacol Ther. 2012 Nov;92(5):584-98
references.pmid: 23047648
references.citation: J Clin Psychopharmacol. 2002 Aug;22(4):419-23
references.pmid: 12172343
references.citation: Clin Pharmacol Ther. 2011 Oct;90(4):582-7
references.pmid: 21866098
references.citation: Eur J Clin Pharmacol. 2000 Aug;56(5):389-94
references.pmid: 11009047
references.citation: Br J Clin Pharmacol. 2006 Mar;61(3):309-14
references.pmid: 16487224
references.citation: Br J Clin Pharmacol. 2011 Apr;71(4):621-3
references.pmid: 21395657
references.citation: Drug Metab Pharmacokinet. 2010;25(1):48-61
references.pmid: 20208388
references.citation: Pediatrics. 2010 Oct;126(4):e986-9
references.pmid: 20837591
references.citation: J Clin Pharmacol. 1995 Jan;35(1):17-21
references.pmid: 7751409
references.citation: Eur J Clin Pharmacol. 2010 Nov;66(11):1131-6
references.pmid: 20669013
references.citation: Clin Pharmacol Ther. 2006 Aug;80(2):126-35
references.pmid: 16890574
references.citation: Postgrad Med J. 2004 Feb;80(940):107-9
references.pmid: 14970301
references.citation: Pharmacol Ther. 2010 Feb;125(2):230-48
references.pmid: 19951720
references.citation: Clin Pharmacol Ther. 1992 Aug;52(2):160-9
references.pmid: 1505151
references.citation: Clin Pharmacol Ther. 1997 Oct;62(4):384-91
references.pmid: 9357389
references.citation: Br J Clin Pharmacol. 2010 Jul;70(1):78-87
references.pmid: 20642550